We are not a conventional equipment manufacturer afraid to try new things. Biopharmaceutical manufacturing experts started the company to create a new type of aseptic filling system with technology as innovative as the drug products made within them.
Cytiva becomes the first “idea-to-injection” biotechnology company by bringing Vanrx into its already strong portfolio.
From drug development, through drug substance and now into drug product, Cytiva can help biomanufacturers bring their therapies to patients faster.
Founded by biopharma manufacturing experts.
Ever wondered why aseptic filling machines all look the same? It’s because pharmaceutical filling machines have not changed in decades. The machines are slow to arrive, inflexible and hard to run reliably. It’s a broken production model that prevents patients from receiving needed medicines.
Vanrx’s founders set out in a different direction. They experienced the frustration of conventional filling machines. Taking inspiration from closed robotic semiconductor manufacturing and combining it with their biopharma knowledge, they created Aseptic Filling Workcells.
Aseptic Filling Workcells are changing the manufacturing landscape.
Today, Vanrx is partnered with some of the world’s most innovative biopharmaceutical companies. Our customers are moving with unprecedented speed and safety in the fights against COVID-19, previously untreatable genetic diseases and deadly superbugs.
Aseptic Filling Workcells—the first standardized, closed robotic aseptic filling machines—allow companies to build and validate filling capacity faster. Customers are then agile in-market as they can pivot between filling different drug products into vials, syringes and cartridges according to market demand.
What’s the latest?
Several customers have recently provided updates about their aseptic filling projects.
ADMA Biologics CEO Adam Grossman said the following after the completion of a site acceptance test for their SA25 Aseptic Filling Workcell: “We believe the SA25 is an easy-to-use, all-in-one solution for our in-house aseptic filling requirements and will allow ADMA to bring our products to patients faster, improve our margins, as well as substantially increase our end-to-end control over our manufacturing process.”
FUJIFILM Diosynth Biotechnologies installed a second SA25 at their College Station, TX site–this one for the manufacturing of recombinant proteins.
Dr. Chris Chen, the CEO of CDMO WuXi Biologics said the following after successful pre-filled syringe production for clients. WuXi Biologics said in the same update that they had 50 filling projects booked on the machine. “Featuring modularization, robotic automation and a closed system, this state-of-the-art line reflects our leadership in biologics manufacturing innovation. DP4 has demonstrated our diverse aseptic filling capabilities, maintaining high product quality and extensive flexibility to serve the complex biologics filling needs of our clients.”
As a result of the company’s continued rapid growth, we are hiring a significant amount of people. There are several available roles in bioprocessing and controls engineering and manufacturing. See the careers page for more details.
Vanrx Pharmasystems is committed to achieving the highest level of operational excellence and customer satisfaction through continual improvements to the quality of our products and services.
Our quality objectives include:
We develop technologies that enable every company to provide safe and affordable injectable medicines to the world.